Non-small cell lung cancer · line 2 · Repotrectinib monotherapy (TRIDENT-1) — ROS1+ NSCLC (TKI-naive or post-prior ROS1-TKI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-REPOTRECTINIB-NSCLC |
| ID | IND-NSCLC-2L-ROS1-REPOTRECTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-TRIDENT1-DRILON-2024 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track for ROS1+ NSCLC; 1L (CROWN-style first-mover) or 2L (post-crizotinib / post-entrectinib with characterized resistance, esp. G2032R).
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Indication
IND-NSCLC-ROS1-1L-REPOTRECTINIB- IND-NSCLC-ROS1-1L-REPOTRECTINIB